Welcome to our dedicated page for ENDRA Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on ENDRA Life Sciences stock.
ENDRA Life Sciences Inc. reports developments in thermoacoustic biomarker imaging, including its TAEUS® Liver device for measuring liver fat in steatotic liver disease, MASLD and MASH. Company news commonly covers clinical feasibility work comparing TAEUS measurements with MRI-PDFF, device repeatability and reproducibility, and business updates tied to operating results.
NDRA updates also include capital and treasury actions, such as private placement financing and a digital asset treasury strategy involving HYPE token holdings and staking. Corporate news has included strategic-review announcements and Nasdaq listing-compliance matters.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present a company overview at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 a.m. Eastern Time on ENDRA's website. ENDRA is known for its innovative technology, Thermo Acoustic Enhanced UltraSound (TAEUS®), which offers a cost-effective alternative to MRI for visualizing tissues, particularly for assessing liver conditions like NAFLD and NASH affecting over one billion people worldwide.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has partnered with King's College Hospital in London for a clinical study to assess the effectiveness of its TAEUS® ultrasound device in diagnosing Non-Alcoholic Fatty Liver Disease (NAFLD). This seventh clinical research partnership aims to compare TAEUS® with the standard MRI method, targeting 75 patients to enhance data diversity. The study will also provide clinical feedback to support ongoing commercialization of TAEUS®, which is already cleared for sale in Europe and has a pending FDA application.
ENDRA Life Sciences (NASDAQ: NDRA) has signed a collaboration agreement with VGI Health Technology to incorporate its TAEUS technology in VGI's upcoming Phase 2 study of IVB001 for Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). This partnership aims to enhance patient screening and biomarker measurement, offering potential cost savings and efficiencies in clinical trial execution. VGI highlights the importance of capturing hepatic steatosis data to improve understanding of NAFLD-NASH, furthering their innovative approach in addressing these conditions.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced the issuance of two new patents by the U.S. Patent and Trademark Office. The patents include U.S. Patent No. 11172829, which enhances thermoacoustic imaging by reducing false signals, and U.S. Patent No. 11176848, which allows for a single phantom for multiple imaging modalities. These patents, the 22nd and 23rd for ENDRA, support the company's strategy to expand the applications of its TAEUS® technology, designed to assess liver conditions affecting over one billion people worldwide.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) announced its Q3 2021 results, reporting a net loss of $2.7 million, or $0.06 per share, improved from a loss of $3.3 million, or $0.15 per share, in Q3 2020. Operating expenses decreased to $2.7 million from $3.3 million, aided by reduced spending on product development. The company reported cash reserves of $11.8 million. Clinical studies at UPMC and RVUCOM are underway, focusing on TAEUS system liver fat measurements versus MRI-PDFF. ENDRA also strengthened its patent portfolio with new U.S. patents.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will announce its third-quarter financial results on November 15, 2021, after the market close. Following the release, management will conduct a conference call at 4:30 p.m. Eastern Time to discuss results and recent developments. Investors can pre-register for the call or access a webcast via the company's Investor Relations page. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), aiming to provide cost-effective diagnostic imaging, particularly for liver conditions affecting over one billion people globally.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has been granted U.S. Patent 11147067, titled “Method And System For Monitoring Tissue Temperature,” enhancing its innovation in Thermo Acoustic Enhanced UltraSound (TAEUS®). This patent complements the earlier U.S. Patent 10631734, both focusing on tissue temperature monitoring during surgical procedures. ENDRA is progressing towards the commercial launch of TAEUS® in Europe and awaits FDA regulatory response for the U.S. market, while its intellectual property portfolio expands to 87 patents, crucial for its strategy in addressing unmet medical needs.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will present at the H.C. Wainwright 5th Annual NASH Investor Conference on October 12, 2021, at 2:00 p.m. Eastern Time. Management will also hold virtual one-on-one meetings with investors throughout the day. ENDRA is known for its innovative Thermo Acoustic Enhanced UltraSound (TAEUS®) technology, which offers cost-effective tissue visualization comparable to MRI, initially targeting liver fat measurement for assessing Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH). For further details, visit www.endrainc.com.
ENDRA Life Sciences (NASDAQ:NDRA) will participate in two virtual investment conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where a recorded presentation will be available on demand starting September 13. The second is the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, with a live presentation on September 21 at 1:15pm ET. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), a technology aimed at visualizing tissue at a fraction of MRI costs, initially focusing on liver health diagnostics.
ENDRA Life Sciences (NASDAQ:NDRA) reported its second-quarter 2021 results, highlighting significant operational developments. The company continues patient screenings at Rocky Vista University and anticipates the University of Pittsburgh Medical Center to start soon. ENDRA initiated in-person sales for its TAEUS system in Europe, supported by a growing patent portfolio of 87 global assets. Despite a net loss of $3.2 million and operating expenses rising to $3.2 million, cash reserves stand at $14 million. CEO Francois Michelon expressed optimism for FDA clearance in 2021, despite potential delays.